BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 6, 2004
View Archived Issues
Comparison of the gastric safety of valdecoxib and naproxen in elderly volunteers
Read More
Three series of COX-2 inhibitors designed at Almirall Prodesfarma
Read More
BMS scientists present two novel series of factor VIIa inhibitors
Read More
Therapeutic benefits of omalizumab in allergy conjunctivitis
Read More
New pharmacokinetic data for ramelteon presented at the ACCP meeting
Read More
Two novel series of chemokine CCR2 antagonists identified at BMS
Read More
Novel anti-HCV agents targeting NS3-NS4A protease claimed by Enanta
Read More
Three series of GSK-3beta inhibitors in early development at Sanofi-Synthelabo
Read More
Japanese team describes flavonoids acting at aldose reductase, AGE formation and free radicals
Read More
Selective topoisomerase I poison for cancer therapy
Read More
Combination treatment with Abbott PARP inhibitor and doxorubicin increases life span
Read More
Analogues of antiangiogenic agent NM-3 show enhanced antiproliferative activity in vivo
Read More
Human monoclonal antibody promising against SARS in vivo
Read More
Provensis continues work to lift Varisolve clinical hold
Read More
SkyePharma and Merck KGaA revise agreement for phase III project
Read More
European submission seeks approval of Dacogen for MDS
Read More
Positive safety data from phase I/II study of HuMax-EGFr
Read More
New phase II study for SDX-101 in CLL commences enrollment
Read More
NABTT studies SDX-102 for brain tumors
Read More
Medarex receives NIAID grants to develop MDX-1303 for anthrax infection
Read More
European approval for Protelos
Read More
No cardiovascular issues in long-term studies of Celebrex
Read More
Dose-ranging study for premature ejaculation compound LI-301
Read More
TACI-Ig cleared to enter phase Ib studies in advanced B-cell malignancies
Read More
Phase III trial of Ikomio for ALS fails to show survival benefit
Read More
Entecavir submitted for U.S., European marketing approval for hepatitis B
Read More
Pro-Pharmaceuticals presents an update on the clinical development of Davanat-1 in cancer
Read More
Therapeutic effects of HepeX-B in patients with chronic HBV infection
Read More
A clinical trial confirms the antibacterial efficacy of telavancin in cSSTI
Read More
Apidra receives European approval
Read More
Febuxostat pharmacokinetics, pharmacodynamics and safety studied
Read More
Antitumor activity of EXEL-7647 observed in vivo
Read More
EXEL-0999 active in solid tumor and leukemia models
Read More
